Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.
Compared with new users of adalimumab (Humira, Abbvie), risk for serious infection was significantly lower among new users of etanercept (Enbrel, Immunex) and ustekinumab (Stelara, Janssen), the researchers wrote. Other drugs had similar levels of risk.
“Current [PsA] treatment guidelines recommend targeted therapies when standard treatments (including non-steroidal